Export 2757 results:
Author Title [ Type(Asc)] Year
Journal Article
P. C. VanVeldhuisen, Walters, M., Sawada, T., Levine, P. H., Wilks, R., Hanchard, B., and Hisada, M., “Seroincidence of human T-lymphotropic virus type I infection and characterization of seroconverters in Jamaican food handlers.”, J Acquir Immune Defic Syndr, vol. 33, no. 3, pp. 387-92, 2003.
P. C. Van Veldhuisen, Walters, M., Sawada, T., Levine, P., Wilks, R., Hanchard, B., and Hisada, M., “Seroincidence of HTLV-I infection and characterization of seroconverters in Jamaican food handlers”, J Acquir Immune Defic Syndr, vol. 33, pp. 387-392, 2003.
S. EK, “Serious cytomegalovirus (CMV) infections following pediatric renal transplantation (RTx): II. Short and long-term effects of viral prophylaxis (PX),”, 1995.
S. EK, “Serious cytomegalovirus (CMV) infections following pediatric renal transplantation (RTx): I. Changing patterns and risk factors,”, 1995.
, “Sensitivity with specificity of a screening questionnaire for dry eye,”, 1996.
N. L. Oden, Lilienfeld, D. E., Lemp, M. A., Nelson, J. D., and Ederer, F., “Sensitivity and specificity of a screening questionnaire for dry eye.”, Adv Exp Med Biol, vol. 438, pp. 807-20, 1998.
G. M. Buck Louis, Sundaram, R., Schisterman, E. F., Sweeney, A., Lynch, C. D., Kim, S., Maisog, J. M., Gore-Langton, R., Eisenberg, M. L., and Chen, Z., “Semen quality and time to pregnancy: the Longitudinal Investigation of Fertility and the Environment Study.”, Fertil Steril, vol. 101, no. 2, pp. 453-62, 2014.
R. A. Annunziato, Bucuvalas, J. C., Yin, W., Arnand, R., Alonso, E. M., Mazariegos, G. V., Venick, R. S., Stuber, M. L., Shneider, B. L., and Shemesh, E., “Self-Management Measurement and Prediction of Clinical Outcomes in Pediatric Transplant.”, J Pediatr, vol. 193, pp. 128-133.e2, 2018.
M. A. Smith, Rubinstein, L., Anderson, J. R., Arthur, D., Catalano, P. J., Freidlin, B., Heyn, R., Khayat, A., Krailo, M., Land, V. J., Miser, J., Shuster, J., and Vena, D., “Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins.”, J Clin Oncol, vol. 17, no. 2, pp. 569-77, 1999.
E. Y. Chew, Clemons, T. E., Sangiovanni, J. Paul, Danis, R. P., Ferris, F. L., Elman, M. J., Antoszyk, A. N., Ruby, A. J., Orth, D., Bressler, S. B., Fish, G. E., Hubbard, G. Baker, Klein, M. L., Chandra, S. R., Blodi, B. A., Domalpally, A., Friberg, T., Wong, W. T., Rosenfeld, P. J., Agrón, E., Toth, C. A., Bernstein, P. S., and Sperduto, R. D., “Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3.”, JAMA Ophthalmol, vol. 132, no. 2, pp. 142-9, 2014.
A. - R. Eye Diseas Group, Chew, E., Clemons, T. E., SanGiovanni, J. P., Danis, R., ,, Elman, M., Antoszyk, A., Ruby, A., Orth, D., Bressler, S., Fish, G., Hubbard, G., Klein, M., Chandra, S., ,, and Sperduto, R., “Secondary Analyses of the Effects of Lutein/Zeaxanthin on Age-Related Macular Degeneration Progression: AREDS 2 Report Number 3”, JAMA Ophthalmol, vol. 132, pp. 142-149, 2014.
B. D. Cheson, Vena, D. A., Barrett, J., and Freidlin, B., “Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias.”, J Clin Oncol, vol. 17, no. 8, pp. 2454-60, 1999.
N. Close, Alejandro, R., Hering, B., Appel, M., and Investigators, T. Collaborat, “Second Annual Analysis of the Collaborative Islet Transplant Registry”, Transplant Proc, vol. 39, pp. 179-182, 2007.
N. Close, Alejandro, R., Hering, B., and Appel, M., “Second annual analysis of the collaborative islet transplant registry.”, Transplant Proc, vol. 39, no. 1, pp. 179-82, 2007.
S. L. Carter, “Search Process”, 2000.
J. J. Elm, Palesch, Y., J Easton, D., Lindblad, A., Barsan, W., Silbergleit, R., Conwit, R., Dillon, C., Farrant, M., Battenhouse, H., Perlmutter, A., and S Johnston, C., “Screen failure data in clinical trials: Are screening logs worth it?”, Clin Trials, vol. 11, no. 4, pp. 467-472, 2014.
I. U. Scott, Figueroa, M. J., Oden, N. L., Ip, M. S., Blodi, B. A., and VanVeldhuisen, P. C., “SCORE2 Report 5: Vision-Related Function in Patients With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion.”, Am J Ophthalmol, vol. 184, pp. 147-156, 2017.
I. U. Scott, Oden, N. L., VanVeldhuisen, P. C., Ip, M. S., and Blodi, B. A., “SCORE2 Report 20: Relationship of Treatment Discontinuation With Visual Acuity and Central Subfield Thickness Outcomes”, Am J Ophthalmol, vol. 248, pp. 157-163, 2023.
I. U. Scott, VanVeldhuisen, P. C., Ip, M. S., Blodi, B. A., Oden, N. L., Figueroa, M., and Dugel, P. U., “SCORE2 Report 2: Study Design and Baseline Characteristics.”, Ophthalmology, vol. 124, no. 2, pp. 245-256, 2017.
I. U. Scott, VanVeldhuisen, P. C., Ip, M. S., Blodi, B. A., Oden, N. L., Figueroa, M., and Dugel, P. U., “SCORE2 Report 2: Study Design and Baseline Characteristics.”, Ophthalmology, vol. 124, no. 2, pp. 245-256, 2017.
I. U. Scott, Oden, N. L., VanVeldhuisen, P. C., Ip, M. S., and Blodi, B. A., “SCORE2 Report 17: Macular Thickness Fluctuations in anti-VEGF-Treated Patients with Central or Hemiretinal Vein Occlusion”, Graefes Arch Clin Exp Ophthalmol, 2021.
A. Hendrick, VanVeldhuisen, P. C., Scott, I. U., King, J., Blodi, B. A., Ip, M. S., Khurana, R. N., and Oden, N. L., “SCORE2 Report 13: Intraretinal Hemorrhage Changes in Eyes With Central or Hemiretinal Vein Occlusion Managed With Aflibercept, Bevacizumab or Observation. Secondary Analysis of the SCORE and SCORE2 Clinical Trials.”, Am J Ophthalmol, vol. 222, pp. 185-193, 2020.
I. U. Scott, VanVeldhuisen, P. C., Ip, M. S., Blodi, B. A., Oden, N. L., and Figueroa, M., “SCORE2 Report 1: Techniques to Optimize Recruitment in Phase III Clinical Trials of Patients With Central Retinal Vein Occlusion.”, Am J Ophthalmol, vol. 170, pp. 25-31, 2016.
N. Oden, VanVeldhuisen, P. C., Scott, I. U., and Ip, M. S., “SCORE Study Report 8: Closed Tests for All Pair-Wise Comparisons of Means.”, Drug Inf J, vol. 44, no. 4, pp. 405-420, 2010.
N. Oden, Van Veldhuisen, P., Scott, I., Ip, M., and Group, S. C. O. R. E. Study Inve, “SCORE Study Report 8: Closed Tests for All Pairwise Comparisons of Means”, Drug Inf J, vol. 44, pp. 405-420, 2010.